Praxis Precision Medicines Inc
Praxis Precision Medicines Inc (PRAX) Unusual Options Activity Today
PRAX options volume power reached 20.13x on the previous trading day. The highest reading was on the $450 CALL expiring 2026-10-16.
Read more
Checking PRAX unusual options activity helps you spot when traders are making outsized bets on Praxis Precision Medicines Inc before the broader market catches on. Praxis Precision Medicines Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor PRAX unusual options activity today and surface the prints that deserve a second look.
Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching PRAX unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking PRAX unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and PRAX unusual options flow data becomes especially valuable around earnings, product launches, and macro events.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy.
It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Catalysts rarely arrive without a footprint, and PRAX unusual options activity is often where that footprint shows up first. Our scanner tracks Praxis Precision Medicines Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at PRAX unusual options volume on the call side or chasing put sweeps, Praxis Precision Medicines Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.
| 450.00 | 0.90 | 2.20 | 1.55 | 92% | 161 | 8 | 2,012.50% |
| 340.00 | 3.30 | 12.00 | 7.65 | 67% | 30 | 24 | 125.00% |
| 310.00 | 12.40 | 21.00 | 16.70 | 67% | 4 | 6 | 66.67% |
| 360.00 | 2.25 | 7.20 | 4.73 | 69% | 1 | 8 | 12.50% |
| 500.00 | — | 3.70 | 3.70 | 132% | 1 | 1,696 | 0.06% |
| 280.00 | 6.00 | 15.20 | 10.60 | 66% | 1 | 3 | 33.33% |
| 165.00 | — | 10.00 | 10.00 | 230% | 0 | 0 | — |
| 170.00 | — | 10.00 | 10.00 | 221% | 0 | 0 | — |
| 175.00 | — | 10.00 | 10.00 | 212% | 0 | 0 | — |
| 180.00 | — | 10.00 | 10.00 | 204% | 0 | 0 | — |
As of September 28, 2026
Spot unusual options activity before it moves
Track PRAX options flow across every expiration, filter by volume power, and find the setups with abnormal activity before the trade is gone.
Start your 14-day free trial→